Loading...
CRSP logo

CRISPR Therapeutics AGNasdaqGM:CRSP Aktierapport

Marknadsvärde US$5.1b
Aktiekurs
n/a
1Y12.7%
7D10.8%
1D12.9%
Portföljens värde
​
Utsikt

CRISPR Therapeutics AG

NasdaqGM:CRSP Aktierapport

Börsvärde: US$5.1b

CRISPR Therapeutics (CRSP) Aktievy

CRISPR Therapeutics AG, ett företag inom genredigering, fokuserar på att utveckla genbaserade läkemedel för allvarliga sjukdomar hos människor med hjälp av sin CRISPR-plattform (Clustered Regularly Interspaced Short Palindromic Repeats)/CRISPR-associated protein 9 (Cas9). Mer information

CRSP fundamental analys
Snöflinga Score
Värdering3/6
Framtida tillväxt5/6
Tidigare resultat0/6
Finansiell hälsa4/6
Utdelningar0/6

Belöningar

Handlar till 72.9% under vår uppskattning av dess verkliga värde

Intäkterna förväntas växa med 68.6% per år

Riskanalys

Inga risker upptäckta för CRSP från våra riskkontroller.

CRSP Community Fair Values

Create Narrative

See what 266 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW460,775 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
460,775 investors already sharing narratives
View all narratives

CRISPR Therapeutics AG Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för CRISPR Therapeutics
Historiska aktiekurser
Aktuell aktiekursUS$59.81
52 veckors högstaUS$78.48
52 veckors lägstaUS$44.12
Beta1.74
1 månads förändring27.28%
3 månaders förändring19.86%
1 års förändring12.70%
3 års förändring18.44%
5 års förändring-52.46%
Förändring sedan börsintroduktionen324.49%

Senaste nyheter och uppdateringar

Analysartikel • Aug 06

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

CRISPR Therapeutics AG ( NASDAQ:CRSP ) just released its latest quarterly results and things are looking bullish...
Seeking Alpha • Aug 05

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

Summary CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026. Company is well-capitalized with $2.36 billion cash, a $600 million ATM facility, and operational runway for at least 24 months. Read the full article on Seeking Alpha
Analysartikel • Jun 20

CRISPR Therapeutics (CRSP) Stock Could Be 69.5% Below Fair Value After Recent Gains

CRISPR Therapeutics (CRSP) shares have caught investor attention after recent trading, with the stock closing at US$54.09. That move comes alongside solid short term returns over the past week and month. See our latest analysis for CRISPR Therapeutics. Looking beyond the latest move, CRISPR Therapeutics shows building short term momentum, with a 7 day share price return of 8.61% and 30 day share price return of 8.40%, set against a 1 year total shareholder return of 22.24% but a weaker 5 year...

Recent updates

Analysartikel • Aug 06

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

CRISPR Therapeutics AG ( NASDAQ:CRSP ) just released its latest quarterly results and things are looking bullish...
Seeking Alpha • Aug 05

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

Summary CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026. Company is well-capitalized with $2.36 billion cash, a $600 million ATM facility, and operational runway for at least 24 months. Read the full article on Seeking Alpha
Analysartikel • Jun 20

CRISPR Therapeutics (CRSP) Stock Could Be 69.5% Below Fair Value After Recent Gains

CRISPR Therapeutics (CRSP) shares have caught investor attention after recent trading, with the stock closing at US$54.09. That move comes alongside solid short term returns over the past week and month. See our latest analysis for CRISPR Therapeutics. Looking beyond the latest move, CRISPR Therapeutics shows building short term momentum, with a 7 day share price return of 8.61% and 30 day share price return of 8.40%, set against a 1 year total shareholder return of 22.24% but a weaker 5 year...
Seeking Alpha • Mar 14

CRISPR Therapeutics: An Uninspiring Start For Casgevy

Summary CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from Casgevy yet, but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy adoption and stiff competition in CAR-T therapies, with no exciting pipeline developments. CRISPR remains a cautious "Hold" within a barbell portfolio, pending momentum from Casgevy's launch and clinical trial success outside rare diseases. Read the full article on Seeking Alpha
Seeking Alpha • Feb 13

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Summary Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth. With major data readouts expected in 2025 and potential Casgevy revenues, CRSP stock remains a compelling investment despite current share price stasis. Read the full article on Seeking Alpha
Seeking Alpha • Jan 16

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Summary CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT program and significant layoffs highlight its precarious position compared to CRISPR's better financial health and strategic advantages. CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Read the full article on Seeking Alpha
Seeking Alpha • Dec 29

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Summary Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024. Despite a slow roll-out, Casgevy's increasing patient demand, reimbursement agreements, and positive long-term efficacy data support a bright revenue outlook and potential profitability by 2028. Crispr's robust pipeline, including CTX310 and CTX320 for cardiovascular diseases, holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects. With $1.9 billion in cash, Crispr has financial stability for at least 3.6 years, supporting ongoing development without needing to raise capital, making it a "buy" for high-risk tolerant investors. Read the full article on Seeking Alpha
Seeking Alpha • Nov 11

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Summary CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals. With nearly $2bn in cash and a promising pipeline, CRISPR Therapeutics remains a compelling long-term investment - I'm anticipating significant developments by 2025. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Crispr Therapeutics: Poised For A Major Turnaround

Summary Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline. Despite competition, Crispr's first-mover advantage, strategic partnerships, and robust pipeline create a durable moat, making it a compelling investment in the biotech sector. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Summary Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. CRSP remains highly shorted, with 20% of shares outstanding sold short. Considering Crispr's secular growth in the long term, perhaps short sellers are betting on near-term negative catalysts. Vertex is exploring an alternative to using Busulfan, which is used to clear out existing patient stem cells; finding a less toxic agent could increase Casgevy's patient population to 150k. Read the full article on Seeking Alpha
Seeking Alpha • Aug 14

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Summary CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns. CRISPR's partnership with Vertex Pharmaceuticals mitigates some operational risks associated with gene therapy. Given the uncertainties, CRISPR Therapeutics stock remains a "hold" until clearer commercial success is evident. Read the full article on Seeking Alpha
Seeking Alpha • Aug 07

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Summary Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future. Crispr made a net loss of $126.4m in Q2, but retains ~$1.7bn of cash, and its pipeline contains assets potentially approvable near term, plus two in-vivo programs offering breakthrough treatments. In my view, Crispr Therapeutics is remains a highly attractive company to invest in with a clear path to >41bn in annual revenues. Read the full article on Seeking Alpha
Seeking Alpha • Jul 13

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Summary CRSP has achieved the highly coveted regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia. However, with revenue recognition only likely from Q4'24 or Q1'25 onwards, readers may want to temper their near-term expectations. At the same time, CRSP does not own the patent of its gene editing technology, with a patent battle still occurring between the two groups of inventors. As the stock continues to trade sideways since November 2021, we believe that its intermediate-term investment thesis is likely tied to its swing trade potential. CRSP is likely to remain volatile as well, attributed to the elevated short interest and intense insider selling, with it only suitable for investors with higher risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Jul 07

Crispr Therapeutics: Beaten Down But Not Broken

Summary CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program. CRSP aims to expand its TAM and reach sustainable profitability over time. I argue why CRSP is close to an inflection point, suggesting buyers should consider capitalizing on its recent pessimism. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Summary CRISPR Therapeutics’ new gene-editing protocol gives it a legitimate claim to be the future of medicine. That powered the stock back in 2020-21. But at some point, it’ll take revenues and profits, not futurism to justify stock ownership. The in-progress launch of Casgevy, a gene-editing treatment for Sickle Cell Disease suggests that transition is closing in. But that’s still getting off the ground, making numbers hard to project, and leaving room for disappointments. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Summary CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the establishment of authorized treatment centers, and CRISPR has already set up more than 25 globally. Despite Q1 revenue missing estimates, the company is controlling expenses and shows a healthy balance sheet with a solid cash runway. The commercial success of Casgevy hinges on long-term patient outcomes and will likely face limited early adoption. Updated investment recommendation: change from "sell" to "hold" due to recent stock valuation adjustments and prudent expense management. Read the full article on Seeking Alpha
Seeking Alpha • May 09

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Transfusion Dependent Beta Thalassemia in the U.S., EU, and other territories, with the potential to "functionally cure" patients. Crispr Therapeutics has a strong balance sheet, a diverse pipeline, and the potential to expand its reach to a larger patient population in the future. Its three targets ex-Casgevy are Type 1 diabetes, immuno-oncology, and in-vivo gene therapy - some compelling progress is being made in each field. In short - what's not to like? One day, Crispr Therapeutics will get the valuation upgrade it deserves. Read the full article on Seeking Alpha
Seeking Alpha • May 03

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

Summary Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile. Crispr Therapeutics stock is also no longer overvalued, as late buyers likely rushed out quickly. The stock's selling intensify has also slowed, allowing dip-buyers an attractive opportunity to load up. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Crispr Therapeutics: Now Is The Time To Buy

Summary Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at least 24 months. Read the full article on Seeking Alpha
Seeking Alpha • Mar 26

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Summary Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insurers are showing interest in covering CASGEVY, providing further support for its commercial launch. Read the full article on Seeking Alpha
Seeking Alpha • Feb 22

Crispr Therapeutics: Cautiously Optimistic

Summary CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR-based therapy for sickle cell disease and beta-thalassemia and has a diverse pipeline targeting various diseases. Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Feb 01

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Summary Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia. In this article I'll look at Casgevy's market potential and its commercialisation challenges. The cost of Casgevy, treatment cons, scalability and accessibility pose serious challenges for widespread adoption. Which may justify the high short interest in the stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Crispr Therapeutics: Commercial Validation Is The Next Step

Summary CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible through an in-vivo solution. The concerns surrounding commercial launch risks are overshadowed by the potential of CRISPR Therapeutics. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Summary CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG and Vertex specifically designed for the treatment of sickle cell disease. Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as the first FDA-approved therapy utilizing CRISPR/Cas9. CASGEVY’s approach involves modifying the patient’s own hematopoietic (blood) stem cells using CRISPR/Cas9 technology. Read the full article on Seeking Alpha

Aktieägarnas avkastning

CRSPUS BiotechsUS Marknad
7D10.8%6.2%-0.8%
1Y12.7%46.3%20.5%

Avkastning vs industri: CRSP presterade sämre än US Biotechs branschen som gav 46.3 % under det senaste året.

Avkastning vs Marknaden: CRSP presterade sämre än US marknaden som gav 20.5 % under det senaste året.

Prisvolatilitet

Is CRSP's price volatile compared to industry and market?
CRSP volatility
CRSP Average Weekly Movement8.1%
Biotechs Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stabil aktiekurs: CRSP har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: CRSP s veckovolatilitet ( 8% ) har varit stabil under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
2013393Sam Kulkarniwww.crisprtx.com

CRISPR Therapeutics AG, ett genredigeringsföretag, fokuserar på att utveckla genbaserade läkemedel för allvarliga mänskliga sjukdomar med hjälp av sin CRISPR/Cas9-plattform (Clustered Regularly Interspaced Short Palindromic Repeats)/CRISPR-associated protein 9). Bolagets CRISPR/Cas9 är en teknik för genredigering, vilket är en process för att exakt ändra specifika sekvenser av genomiskt DNA. Bolaget har en portfölj av terapeutiska program inom en rad olika sjukdomsområden, inklusive hemoglobinopatier, CAR T-cellsterapier, in vivo, och typ 1-diabetes, samt utvecklar CAR T-program, inklusive ett autologt, genredigerat CAR T-program inriktat på allogena chimära antigenreceptor T-celler för autoimmuna indikationer och onkologi.

CRISPR Therapeutics AG Sammanfattning av grunderna

Hur förhåller sig CRISPR Therapeutics:s resultat och omsättning till dess börsvärde?
CRSP grundläggande statistik
BörsvärdeUS$5.12b
Vinst(TTM)-US$451.14m
Intäkter(TTM)US$13.39m
431.8x
P/S-förhållande
-12.8x
P/E-förhållande

Är CRSP övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
CRSP resultaträkning (TTM)
IntäkterUS$13.39m
Kostnad för intäkterUS$475.19m
Bruttovinst-US$461.80m
Övriga kostnader-US$10.66m
Intäkter-US$451.14m

Senast redovisade vinst

Jun 30, 2026

Nästa vinstdatum

n/a

Vinst per aktie (EPS)-4.67
Bruttomarginal-3,448.33%
Nettovinstmarginal-3,368.72%
Skuld/egenkapitalförhållande33.6%

Hur har CRSP utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/08/19 15:37
Aktiekurs vid dagens slut2026/08/19 00:00
Intäkter2026/06/30
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

CRISPR Therapeutics AG bevakas av 40 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Jack AllenBaird
William PickeringBernstein
Alec StranahanBofA Global Research